Brooks Nader opened up about her health struggles in a recent interview with Bustle published on Nov. 5 The model admitted to her continued use of GLP-1, despite knowing it's "not healthy" for her She ...

Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...

The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. | The Trump administration has unveiled yet another new payment model, this one ...